SETD3

Across TCGA pan-cancer cohorts, SETD3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SETD3 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SETD3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SETD3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where SETD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.834	<.001	77	view →
UCEC	OS	Tertile	All	1.000	0.881	.012	22	view →
LSCC	DFS	Tertile	III,IV	1.000	0.494	.025	11	view →
GBM	OS	Median	All	0.241	0.564	.009	4	view →
PDAC	OS	Median	II,III,IV	0.500	0.257	.013	4	view →
LUAD	DFS	Quartile	All	0.635	0.857	.029	4	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SETD3–CCRCC (DFS)

Open the CCRCC breakdown →